Wells Fargo initiated coverage of GH Research PLC (GHRS) with an Overweight rating. The investment bank set a price target of $44 for the stock.
Analysts highlighted the potential of GH001, a lead product candidate for treating depression. The firm suggests that current market valuations do not fully reflect positive Phase 2b trial results.
The consensus rating among analysts remains a Moderate Buy. Institutional investor Troluce Capital Advisors LLC recently reported a significant increase in its GH Research holdings.